TransCode Therapeutics (RNAZ) Publishes Open Letter to Shareholders, Proposed Reverse Split

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to TransCode Therapeutics (RNAZ) Publishes Open Letter to Shareholders, Proposed Reverse Split

TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives

January 4, 2024 8:05 AM EST

Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic Disease

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (TransCode or the Company) (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced publication of an open letter to shareholders outlining the Companys progress in 2023 and objectives in 2024. The text of the letter is below.

Dear Shareholders,

... More